MedElevator Войти в исследования
← Поиск публикаций

DOI 10.3390/cancers15174359

Медицинская библиотека · Cancers · 2023

Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.

Avivi Irit, Vesole David H, Davila-Valls Julio, Usnarska-Zubkiewicz Lidia, Olszewska-Szopa Magdalena, Milunovic Vibor, Baumert Bartłomiej, Osękowska Bogumiła, Kopińska Anna, Gentile Massimo, Puertas-Martinez Borja, Robak Paweł, Crusoe Edvan, Rodriguez-Lobato Luis Gerardo, Gajewska Małgorzata, Varga Gergely, Delforge Michel, Cohen Yael, Gozzetti Alessandro, Pena Camila, Shustik Chaim, Mikala Gabor, Zalac Klara, Alexander H Denis, Barth Peter, Weisel Katja, Martínez-López Joaquín, Waszczuk-Gajda Anna, Krzystański Mateusz, Jurczyszyn Artur

СтатьяПеревод пока не подготовлен

Аннотация

BACKGROUND

There is an increased risk of second primary malignancies (SMPs) in patients with multiple myeloma (MM). This multinational 'real-world' retrospective study analyzed the characteristics and outcomes of MM patients that developed SPMs.

RESULTS

165 patients were analyzed: 62.4% males; 8.5% with a prior cancer; 113 with solid SPMs, mainly ≥stage 2; and 52 with hematological SPM (hemato-SPM), mainly MDS/AML. Patients with hemato-SPM were younger (p = 0.05) and more frequently had a prior AutoHCT (p = 0.012). The time to SPM was shorter in the older (>65 years) and more heavily pretreated patients. One hundred patients were actively treated at the time of SPM detection. Treatment was discontinued in 52, substituted with another anti-MM therapy in 15, and continued in 33 patients. Treatment discontinuation was predominant in the patients diagnosed with hemato-SPM (76%). The median OS following SPM detection was 8.5 months, and the main cause of death was SPM. A poor ECOG status predicted a shorter OS (PS 3 vs. 0, HR = 5.74, 2.32-14.21, p < 0.001), whereas a normal hemoglobin level (HR = 0.43, 0.19-0.95, p = 0.037) predicted longer OS.

CONCLUSIONS

With the continuing improvement in OS, a higher proportion of MM patients might develop SPM. The OS following SPM diagnosis is poor; hence, frequent surveillance and early detection are imperative to improve outcomes.

Для цитирования: Avivi Irit, Vesole David H, Davila-Valls Julio, Usnarska-Zubkiewicz Lidia, Olszewska-Szopa Magdalena, Milunovic Vibor, Baumert Bartłomiej, Osękowska Bogumiła, Kopińska Anna, Gentile Massimo, Puertas-Martinez Borja, Robak Paweł, Crusoe Edvan, Rodriguez-Lobato Luis Gerardo, Gajewska Małgorzata, Varga Gergely, Delforge Michel, Cohen Yael, Gozzetti Alessandro, Pena Camila, Shustik Chaim, Mikala Gabor, Zalac Klara, Alexander H Denis, Barth Peter, Weisel Katja, Martínez-López Joaquín, Waszczuk-Gajda Anna, Krzystański Mateusz, Jurczyszyn Artur. Outcome of Second Primary Malignancies Developing in Multiple Myeloma Patients.. Cancers. 2023. DOI: 10.3390/cancers15174359.
Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.